Literature DB >> 9326416

Xenogeneic endothelial cells activate human prothrombin.

J B Siegel1, S T Grey, B A Lesnikoski, C W Kopp, M Soares, J Schulte am Esch, F H Bach, S C Robson.   

Abstract

BACKGROUND: Delayed xenograft rejection is characterized by platelet activation and fibrin deposition and is thought to occur independently of complement activation. We have therefore investigated the potential for xenogeneic endothelial cells (EC) to regulate the conversion of prothrombin to thrombin, a central component of the final common pathway of coagulation and an important platelet agonist. METHODS AND
RESULTS: Quiescent porcine aortic EC (PAEC) were found to convert high levels of human prothrombin to thrombin (0.234+/-0.019 IU/ml) when compared with human aortic EC (0.017+/-0 IU/ml, 30-min time point, chromogenic assay; P<0.001). PAEC activation by human complement resulted in comparable levels of thrombin generation. Prothrombin conversion by PAEC as determined by generation of F1+2 (1.909+/-0.119 nmol/L) and formation of thrombin-antithrombin III complexes (125.611+/-6.373 microg/L) was significantly greater than the matched human aortic EC values (F1+2: 1.539+/-0.03 nmol/L, P<0.001; thrombin-antithrombin III: 1.833+/-0.104 microg/L, P<0.001). Sequential analysis of prothrombin activation by PAEC indicated generation of the intermediate meizothrombin followed by autolytically accelerated thrombin formation. Subsequent experiments established important cross-species' incompatibilities with respect to porcine thrombomodulin interaction with human thrombin and protein C in that PAEC had a reduced capacity to generate activated human protein C in vitro.
CONCLUSION: These observations indicate a potentially important molecular barrier involving blood coagulation that may impact on the planned clinical application of porcine transgenic organs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326416     DOI: 10.1097/00007890-199709270-00017

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  Xenotransplantation as a model of integrated, multidisciplinary research.

Authors:  Emanuele Cozzi; Erika Bosio; Michela Seveso; Domenico Rubello; Ermanno Ancona
Journal:  Organogenesis       Date:  2009-01       Impact factor: 2.500

2.  Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens.

Authors:  Hayato Iwase; Burcin Ekser; Vikas Satyananda; Jay Bhama; Hidetaka Hara; Mohamed Ezzelarab; Edwin Klein; Robert Wagner; Cassandra Long; Jnanesh Thacker; Jiang Li; Hao Zhou; Maolin Jiang; Santosh Nagaraju; Huidong Zhou; Massimiliano Veroux; Pietro Bajona; Martin Wijkstrom; Yi Wang; Carol Phelps; Nikolai Klymiuk; Eckhard Wolf; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2015-04-03       Impact factor: 3.907

Review 3.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 4.  Lung xenotransplantation: recent progress and current status.

Authors:  Donald G Harris; Kevin J Quinn; Siamak Dahi; Lars Burdorf; Agnes M Azimzadeh; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-07-05       Impact factor: 3.907

Review 5.  Controlling coagulation dysregulation in xenotransplantation.

Authors:  Peter J Cowan; Simon C Robson; Anthony J F d'Apice
Journal:  Curr Opin Organ Transplant       Date:  2011-04       Impact factor: 2.640

6.  Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation.

Authors:  Guerard W Byrne; Paul G Stalboerger; Eduardo Davila; Carrie J Heppelmann; Mozammel H Gazi; Hugh C J McGregor; Peter T LaBreche; William R Davies; Vinay P Rao; Keiji Oi; Henry D Tazelaar; John S Logan; Christopher G A McGregor
Journal:  Xenotransplantation       Date:  2008 Jul-Aug       Impact factor: 3.907

7.  Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice.

Authors:  S Crikis; X M Zhang; S Dezfouli; K M Dwyer; L M Murray-Segal; E Salvaris; C Selan; S C Robson; H H Nandurkar; P J Cowan; A J F d'Apice
Journal:  Am J Transplant       Date:  2010-01-06       Impact factor: 8.086

8.  Platelet aggregation in humans and nonhuman primates: relevance to xenotransplantation.

Authors:  Hayato Iwase; Burcin Ekser; Hao Zhou; Eefje M Dons; David K C Cooper; Mohamed B Ezzelarab
Journal:  Xenotransplantation       Date:  2012 Jul-Aug       Impact factor: 3.907

Review 9.  Immunobiology of liver xenotransplantation.

Authors:  Burcin Ekser; Christopher Burlak; Joshua P Waldman; Andrew J Lutz; Leela L Paris; Massimiliano Veroux; Simon C Robson; Michael A Rees; David Ayares; Bruno Gridelli; A Joseph Tector; David Kc Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-09       Impact factor: 4.473

10.  Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation.

Authors:  Karen M Dwyer; Simon C Robson; Harshal H Nandurkar; Duncan J Campbell; Hilton Gock; Lisa J Murray-Segal; Nella Fisicaro; Tharun B Mysore; Elzbieta Kaczmarek; Peter J Cowan; Anthony J F d'Apice
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.